Objective：To investigate the expression and clinical pathological significance of long noncoding RNA（LncRNA）MCM3AP-AS1 in breast cancer patients. Methods：A total of 64 cases of tumor tissue puncture specimens were collected from elderly women（age≥60）with advanced breast cancer. The expression of LncRNA MCM3AP-AS1 in tumor tissues of these patients was detected by qRT-PCR. The expressions of ER，PR，Her-2，Ki-67 and Dkk1 protein in breast cancer tissue samples were detected by immunohistochemistry. Samples with immunohistochemical Her-2 2+ were further tested by FISH. Furthermore，we analyzed the relationship between LncRNA MCM3AP-AS1 expression and clinical pathology of breast cancer patients and its impact on prognosis. Results：The expression of LncRNA MCM3AP-AS1 was significantly increased in breast cancer patients with poor tissue differentiation and ER（-），PR（-）（P < 0.01）. The expression of LncRNA MCM3AP-AS1 was not associated with the presence of liver，lung or brain metastasis，but was closely related to bone metastasis（P < 0.01）. Patients with ER（-），PR（-），Her-2（+） or Dkk1（+）were more likely to have bone metastases（P < 0.01）. The progression-free survival of breast cancer patients with high expression of LncRNA MCM3AP-AS1 was significantly shorter than that of low expression group（P < 0.01）. Conclusion：LncRNA MCM3AP-AS1 is closely related to the malignant biological behavior of female breast cancer. The detection of LncRNA MCM3AP-AS1 expression has potential value in helping us to better understand the mechanism of breast cancer and judging the prognosis of breast cancer patients.